Summary of Significant Accounting Policies (Tables)

12 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Customer Information

Significant customer information is as follows:

	Year Ended March 31,
	2022			2021
Percentage of accounts receivable:
Customer G		44	%		0	%
Customer C		25	%		35	%
Customer F		19	%		0	%
Customer D		0	%		40	%

	Year Ended March 31,
	2022			2021			2020
Percentage of revenue:
Customer C		20	%		21	%		25	%
Customer B		17	%		16	%		8	%

Summary Of Revenue By Category

The following table presents revenue by category:

	Year Ended March 31,
	2022					2021					2020
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)
Point in Time
PGS	$	189,703		70	%	$	191,066		78	%	$	263,679		86	%
Telehealth (1)		15,299		6	%		—		0	%		—		0	%
Consumer services		205,002		76	%		191,066		78	%		263,679		86	%
Research services		—		0	%		—		0	%		—		0	%
Therapeutics		—		0	%		54		0	%		5,556		2	%
Total	$	205,002		76	%	$	191,120		78	%	$	269,235		88	%
Over Time
PGS	$	12,978		5	%	$	6,459		3	%	$	7,960		3	%
Telehealth (1)		3,908		1	%		—		0	%		—		0	%
Consumer services		16,886		6	%		6,459		3	%		7,960		3	%
Research services		50,005		18	%		46,341		19	%		28,268		9	%
Therapeutics		—		0	%		—		0	%		—		0	%
Total	$	66,891		24	%	$	52,800		22	%	$	36,228		12	%
Total Revenue
PGS	$	202,681		75	%	$	197,525		81	%	$	271,639		89	%
Telehealth (1)		19,207		7	%		—		0	%		—		0	%
Consumer services		221,888		82	%		197,525		81	%		271,639		89	%
Research services		50,005		18	%		46,341		19	%		28,268		9	%
Therapeutics		—		0	%		54		0	%		5,556		2	%
Total	$	271,893		100	%	$	243,920		100	%	$	305,463		100	%

(1)For the year ended March 31, 2022, telehealth revenue included the five month period from the close of the acquisition of Lemonaid Health on November 1, 2021 through March 31, 2022.

Summary of Revenue by Region based on the Shipping Address of Customers

The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered:

	Year Ended March 31,
	2022					2021					2020
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)
United States	$	192,438		71	%	$	176,120		72	%	$	241,769		79	%
United Kingdom		58,477		22	%		49,386		20	%		41,770		14	%
Canada		14,293		5	%		12,172		5	%		14,481		5	%
Other regions		6,685		2	%		6,242		3	%		7,443		2	%
International		79,455		29	%		67,800		28	%		63,694		21	%
Total	$	271,893		100	%	$	243,920		100	%	$	305,463		100	%

Schedule of estimated useful lives of property, plant and equipment

The estimated useful lives of the Company’s property and equipment are as follows:

Computer and software	3 years
Laboratory equipment and software	5 years
Furniture and office equipment	5 years
Leasehold improvements	Shorter of remaining lease term or estimated useful life

Schedule Of Company Revenue and Adjusted EBITDA by Segment

The Company’s revenue and Adjusted EBITDA by segment is as follows:

	Year Ended March 31,
	2022			2021			2020
	(in thousands)
Segment Revenue
Consumer and Research Services	$	271,893		$	243,866		$	299,907
Therapeutics		—			54			5,556
Total Revenue	$	271,893		$	243,920		$	305,463
Segment Adjusted EBITDA
Consumer and Research Services Adjusted EBITDA	$	(30,112	)	$	12,796		$	(65,845	)
Therapeutics Adjusted EBITDA		(76,944	)		(58,734	)		(52,883	)
Unallocated Corporate		(43,684	)		(30,587	)		(28,460	)
Total Adjusted EBITDA	$	(150,740	)	$	(76,525	)	$	(147,188	)
Reconciliation of net loss to Adjusted EBITDA
Net Loss	$	(217,490	)	$	(183,619	)	$	(250,863	)
Adjustments:
Interest (income) expense, net		(277	)		(255	)		(6,244	)
Other (income) expense, net		83			(1,322	)		(1,340	)
Change in fair value of warrant liabilities		(32,989	)		—			—
Income tax benefit		(3,480	)		—			—
Depreciation and amortization		18,899			20,246			22,610
Amortization of acquired intangible assets		7,269			—			—
Stock-based compensation expense		57,933			88,425			43,957
Restructuring and other charges (1)		—			—			44,692
Acquisition-related costs (2)		9,362			—			—
Litigation settlement (3)		9,950			—			—
Total Adjusted EBITDA	$	(150,740	)	$	(76,525	)	$	(147,188	)

(1)For the year ended March 31, 2020, restructuring includes $0.9 million of stock-based compensation expense related to restructuring activities.

(2)For the fiscal year ended March 31, 2022, acquisition-related costs primarily consisted of advisory, legal and consulting fees related to the Lemonaid Acquisition.

(3)For the fiscal year ended March 31, 2022, litigation settlement is litigation cost net of insurance recoveries, which is not expected to occur on a recurring basis and not part of the Company's normal and continued business activity.

Summary of Customers Accounting for 10% or More of Segment Revenues

Customers accounting for 10% or more of segment revenues were as follows:

	Year Ended March 31,
	2022				2021				2020
	(in thousands, except percentages)
Consumer and Research Services Segment Revenue:
Customer C(1)	$	53,875	20	%	$	51,786	21	%	$	76,087	25	%
Customer B(2)	$	46,064	17	%	$	39,917	16	%	$	23,768	8	%
Therapeutics Segment Revenue:
Customer B(2)	$	—	0	%	$	—	0	%	$	2,981	54	%
Customer E(2)	$	—	0	%	$	54	100	%	$	2,575	46	%

(1)Customer C revenues are primarily in the United States.

(2)Customer B revenues are in the U.K. and Customer E is in a region other than the United States, U.K., or Canada.